A highly sensitive particle agglutination assay for the detection of p53 Autoantibodies in patients with lung cancer

Agaylan A, Binder D, Sauer M, Neuweiler H, Meyer O, Kiesewetter H, Salama A (2007)
Cancer 110(11): 2502-2506.

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ; ;
Abstract
BACKGROUND. Numerous assays have been described for the detection of p53 autoantibodies. These assays are highly specific with low sensitivity. In this report, the authors describe a highly sensitive and simple particle agglutination immunoassay using superparamagnetic particles for capturing p5 autoantibodies, p53 protein, and p53 protein-antibody complexes from large volumes of serum samples (2 mL). METHODS. Superparamagnetic particles were coated with different peptides spanning the entire p53 protein. These particles were incubated with serum samples from healthy blood donors (n = 180), from patients without malignancies (n = 27), and from patients with various forms of lung cancer (n = 166). The particles were washed and placed into the reaction chamber of a gel card. After centrifugation, agglutination results were read visually. Positive reactions were defined by a layer of particles on top of the gel or agglutinated particles dispersed through the gel matrix. RESULTS. Depending on the peptide used, p53 autoantibodies were detected in from 17.5% to 35% of the investigated patients with lung cancer. By using a commercially available enzyme-linked immunoadsorbent assay (ELISA) kit, p53 autoantibodies were detected in only 3% of those patients. P53 protein and p53 protein-antibody complexes were not detected in patients with lung cancer (n = 20). CONCLUSIONS. The newly developed assay was easy to perform and had sensitivity superior to that of the currently available p53 ELISAs.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Agaylan A, Binder D, Sauer M, et al. A highly sensitive particle agglutination assay for the detection of p53 Autoantibodies in patients with lung cancer. Cancer. 2007;110(11):2502-2506.
Agaylan, A., Binder, D., Sauer, M., Neuweiler, H., Meyer, O., Kiesewetter, H., & Salama, A. (2007). A highly sensitive particle agglutination assay for the detection of p53 Autoantibodies in patients with lung cancer. Cancer, 110(11), 2502-2506.
Agaylan, A., Binder, D., Sauer, M., Neuweiler, H., Meyer, O., Kiesewetter, H., and Salama, A. (2007). A highly sensitive particle agglutination assay for the detection of p53 Autoantibodies in patients with lung cancer. Cancer 110, 2502-2506.
Agaylan, A., et al., 2007. A highly sensitive particle agglutination assay for the detection of p53 Autoantibodies in patients with lung cancer. Cancer, 110(11), p 2502-2506.
A. Agaylan, et al., “A highly sensitive particle agglutination assay for the detection of p53 Autoantibodies in patients with lung cancer”, Cancer, vol. 110, 2007, pp. 2502-2506.
Agaylan, A., Binder, D., Sauer, M., Neuweiler, H., Meyer, O., Kiesewetter, H., Salama, A.: A highly sensitive particle agglutination assay for the detection of p53 Autoantibodies in patients with lung cancer. Cancer. 110, 2502-2506 (2007).
Agaylan, Ashraf, Binder, Daniel, Sauer, Markus, Neuweiler, Hannes, Meyer, Oliver, Kiesewetter, Holger, and Salama, Abdulgabar. “A highly sensitive particle agglutination assay for the detection of p53 Autoantibodies in patients with lung cancer”. Cancer 110.11 (2007): 2502-2506.
This data publication is cited in the following publications:
This publication cites the following data publications:

21 References

Data provided by Europe PubMed Central.

Comparative study of the role of serum levels of p53 antigen and its tumor cell concentration in colon cancer detection.
Zusman I, Sandler B, Gurevich P, Zusman R, Smirnoff P, Tendler Y, Bass D, Shani A, Idelevich E, Pfefferman R, Davidovich B, Huszar M, Glick J., Hum. Antibodies Hybridomas 7(3), 1996
PMID: 9057060
Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens.
Dowell SP, Wilson PO, Derias NW, Lane DP, Hall PA., Cancer Res. 54(11), 1994
PMID: 8187077
DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies.
Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B, Slamon DJ., Oncogene 13(9), 1996
PMID: 8934544
p53 antibodies in patients with various types of cancer: assay, identification, and characterization.
Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild CP., Clin. Cancer Res. 1(12), 1995
PMID: 9815945
Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface.
Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Tredaniel J, Hirsch A, Caron de Fromentel C, Preudhomme C, Fenaux P, Fournier G, Mangin P, Laurent-Puig P, Pelletier G, Schlumberger M, Desgrandchamps F, Le Duc A, Peyrat JP, Janin N, Bressac B, Soussi T., Cancer Res. 53(24), 1993
PMID: 8261396
p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage.
Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD, Berger SL., Mol. Cell. Biol. 19(2), 1999
PMID: 9891054
p53 protein is absent from the serum of patients with lung cancer.
Levesque MA, D'Costa M, Diamandis EP., Br. J. Cancer 74(9), 1996
PMID: 8912541
Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.
Zalcman G, Schlichtholz B, Tredaniel J, Urban T, Lubin R, Dubois I, Milleron B, Hirsch A, Soussi T., Clin. Cancer Res. 4(6), 1998
PMID: 9626451
Detection of anti-p53 antibodies by ELISA using p53 synthetic or phage-displayed peptides.
Portefaix JM, Fanutti C, Granier C, Crapez E, Perham R, Grenier J, Pau B, Del Rio M., J. Immunol. Methods 259(1-2), 2002
PMID: 11730842
Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes.
Vennegoor CJ, Nijman HW, Drijfhout JW, Vernie L, Verstraeten RA, von Mensdorff-Pouilly S, Hilgers J, Verheijen RH, Kast WM, Melief CJ, Kenemans P., Cancer Lett. 116(1), 1997
PMID: 9177463
Levels of p53 antigen in the plasma of patients with adenomas and carcinomas of the colon.
Luo JC, Neugut AI, Garbowski G, Forde KA, Treat M, Smith S, Carney WP, Brandt-Rauf PW., Cancer Lett. 91(2), 1995
PMID: 7767914
Rapid detection of antibodies to immunoglobulin A molecules by using the particle gel immunoassay.
Salama A, Schwind P, Schonhage K, Genth R, Cotting C, Hustinx H, Krieg R, Nydegger U, Aebischer I., Vox Sang. 81(1), 2001
PMID: 11520416
Rapid and sensitive immunomagnetic-electrochemiluminescent detection of p53 antibodies in human serum.
Yan G, Xing D, Tan S, Chen Q., J. Immunol. Methods 288(1-2), 2004
PMID: 15183084
Serum p53 antibodies as early markers of lung cancer.
Lubin R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Cazals D, Hirsch A, Soussi T., Nat. Med. 1(7), 1995
PMID: 7585154
A simple and practical agglutination assay for human leucocyte antigen-B27 typing.
Meyer O, Abdallah Z, Schonemann C, Hugo F, Agaylan A, Kiesewetter H, Salama A., Vox Sang. 91(1), 2006
PMID: 16756605
A novel antigen-specific capture assay for the detection of platelet antibodies and HPA-1a phenotyping.
Meyer O, Agaylan A, Bombard S, Kiesewetter H, Salama A., Vox Sang. 91(4), 2006
PMID: 17105608
Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer.
Crawford LV, Pim DC, Bulbrook RD., Int. J. Cancer 30(4), 1982
PMID: 6292117
Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers.
Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS., Int. J. Cancer 58(4), 1994
PMID: 8056443

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 17932907
PubMed | Europe PMC

Search this title in

Google Scholar